Use of Intravitreal Bevacizumab in Patients With Diffuse Diabetic Macular Edema

• Status: Unknown status
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Intravitreal Bevacizumab is an effective treatment for the diffuse diabetic macular edema

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Type 2 diabetes

• Macular edema involving the center of the macula demonstrated on OCT

• Clear ocular media

• Untreated patients

• Older than 45 years

• BCVA of the fellow eye at least 20/100

Exclusion Criteria:

• Renal diabetic disease, uncontrolled hypertension or stroke history

• Other ocular disease

• Ocular surgery excepting uncomplicated phacoemulsification

• History of photocoagulation (panretinal or focal)

• History of another intravitreal treatment (like triamcinolone)